BNP Paribas Analysts Give AstraZeneca plc (AZN) a GBX 5,800 Price Target
AstraZeneca plc (LON:AZN) has been assigned a GBX 5,800 ($78.00) price objective by stock analysts at BNP Paribas in a research report issued to clients and investors on Monday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. BNP Paribas’ price objective suggests a potential upside of 18.08% from the stock’s current price.
Several other equities research analysts have also commented on AZN. J P Morgan Chase & Co restated a “neutral” rating on shares of AstraZeneca plc in a research report on Monday, May 29th. Deutsche Bank AG set a GBX 5,700 ($76.65) target price on shares of AstraZeneca plc and gave the stock a “buy” rating in a research report on Monday, May 29th. Jefferies Group LLC set a GBX 4,700 ($63.21) target price on shares of AstraZeneca plc and gave the stock a “neutral” rating in a research report on Monday, May 29th. Goldman Sachs Group, Inc. (The) restated a “sell” rating and set a GBX 3,900 ($52.45) target price on shares of AstraZeneca plc in a research report on Thursday, June 1st. Finally, Shore Capital restated a “hold” rating on shares of AstraZeneca plc in a research report on Friday, June 2nd. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of GBX 5,111.27 ($68.74).
TRADEMARK VIOLATION NOTICE: This news story was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/09/25/bnp-paribas-analysts-give-astrazeneca-plc-azn-a-gbx-5800-price-target.html.
In other news, insider Nazneen Rahman bought 39 shares of the firm’s stock in a transaction dated Thursday, July 27th. The stock was acquired at an average price of GBX 4,370 ($58.77) per share, for a total transaction of £1,704.30 ($2,291.96).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.